398,782 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners acquired 398,782 Amylyx Pharmaceuticals shares worth approximately $7.2 million, while institutional investors collectively owned 95.84% of the company.
• Analyst sentiment remains broadly positive: Amylyx has a consensus “Buy” rating and an average price target of $36.25, though some firms maintain sell ratings.
• AMLX opened at $38.15, near its 52-week high of $41.14, but the company recently reported a quarterly loss of $0.39 per share, missing estimates by $0.03.

Parkman Healthcare Partners LLC purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 398,782 shares of the company's stock, valued at approximately $7,162,000. Parkman Healthcare Partners LLC owned approximately 0.36% of Amylyx Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth about $158,534,000. Adage Capital Partners GP L.L.C. grew its stake in shares of Amylyx Pharmaceuticals by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company's stock valued at $56,408,000 after buying an additional 3,102,395 shares in the last quarter. Millennium Management LLC grew its stake in shares of Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company's stock valued at $10,910,000 after buying an additional 2,487,617 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Amylyx Pharmaceuticals by 76.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company's stock valued at $53,992,000 after buying an additional 1,929,639 shares during the period. Finally, Paradigm Biocapital Advisors LP purchased a new stake in shares of Amylyx Pharmaceuticals during the 3rd quarter valued at about $25,821,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMLX. HC Wainwright upped their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Citigroup boosted their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $36.25.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX opened at $38.15 on Tuesday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $8.47 and a 1 year high of $41.14. The stock's 50-day simple moving average is $20.83 and its 200-day simple moving average is $16.87. The firm has a market cap of $4.25 billion, a price-to-earnings ratio of -26.68 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). As a group, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Amylyx Pharmaceuticals Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source